{"doi":"10.1126/sciadv.ado2048","title":"Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo","abstract":"<jats:p>\n            Adoptive T cell therapy (ACT), the therapeutic transfer of defined T cell immunity to patients, offers great potential in the fight against different human diseases including difficult-to-treat viral infections, but persistence and longevity of the cells are areas of concern. Very-early-differentiated stem cell memory T cells (T\n            <jats:sub>SCMs</jats:sub>\n            ) have superior self-renewal, engraftment, persistence, and anticancer efficacy, but their potential for antiviral ACT remains unknown. Here, we developed a clinically scalable protocol for expanding Epstein-Barr virus (EBV)–specific T\n            <jats:sub>SCM</jats:sub>\n            -enriched T cells with high proportions of CD4\n            <jats:sup>+</jats:sup>\n            T cells and broad EBV antigen coverage. These cells showed tumor control in a xenograft model of EBV-induced lymphoma and were superior to previous ACT protocols in terms of tumor infiltration, in vivo proliferation, persistence, proportion of functional CD4\n            <jats:sup>+</jats:sup>\n            T cells, and diversity of EBV antigen specificity. Thus, our protocol may pave the way for the next generation of potent unmodified antigen-specific cell therapies for EBV-associated diseases, including tumors, and other indications.\n          </jats:p>","journal":"Science Advances","year":2024,"id":649972,"datarank":0.3453877639491069,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.0,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1694637,"name":"Juliane Mietz","orcid":"0009-0007-9359-2242","position":1,"is_corresponding":false},{"id":1694640,"name":"Claudia Stühler","orcid":null,"position":2,"is_corresponding":false},{"id":1694642,"name":"Brice Arnold","orcid":null,"position":3,"is_corresponding":false},{"id":938135,"name":"Glenn R. Bantug","orcid":"0000-0003-2253-6028","position":4,"is_corresponding":false},{"id":263547,"name":"Christian Münz","orcid":"0000-0001-6419-1940","position":5,"is_corresponding":false},{"id":687555,"name":"Obinna Chijioke","orcid":"0000-0003-4247-5947","position":6,"is_corresponding":false},{"id":76119,"name":"Nina Khanna","orcid":"0000-0002-2642-419X","position":7,"is_corresponding":false},{"id":1694635,"name":"Darya Palianina","orcid":"0000-0003-1785-7548","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo","abstract":"<jats:p>\n            Adoptive T cell therapy (ACT), the therapeutic transfer of defined T cell immunity to patients, offers great potential in the fight against different human diseases including difficult-to-treat viral infections, but persistence and longevity of the cells are areas of concern. Very-early-differentiated stem cell memory T cells (T\n            <jats:sub>SCMs</jats:sub>\n            ) have superior self-renewal, engraftment, persistence, and anticancer efficacy, but their potential for antiviral ACT remains unknown. Here, we developed a clinically scalable protocol for expanding Epstein-Barr virus (EBV)–specific T\n            <jats:sub>SCM</jats:sub>\n            -enriched T cells with high proportions of CD4\n            <jats:sup>+</jats:sup>\n            T cells and broad EBV antigen coverage. These cells showed tumor control in a xenograft model of EBV-induced lymphoma and were superior to previous ACT protocols in terms of tumor infiltration, in vivo proliferation, persistence, proportion of functional CD4\n            <jats:sup>+</jats:sup>\n            T cells, and diversity of EBV antigen specificity. Thus, our protocol may pave the way for the next generation of potent unmodified antigen-specific cell therapies for EBV-associated diseases, including tumors, and other indications.\n          </jats:p>","is_dataset_classified":null,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39178248","pmcid":"PMC11343021","openalex_id":"https://openalex.org/W4401806719","authors":[],"funders":[{"funder_name":"Swiss National Science Foundation","grant_id":"204944","title":null}],"total_grants":1,"fwci":1.6159,"citation_percentile":0.86251161,"influential_citations":0,"citation_trend":[{"year":2024,"count":1},{"year":2025,"count":6},{"year":2026,"count":2}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://doi.org/10.1126/sciadv.ado2048","host_type":"journal"},{"url":"https://doi.org/10.1126/sciadv.ado2048","host_type":"publisher"},{"url":"https://www.science.org/doi/pdf/10.1126/sciadv.ado2048","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39178248","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11343021","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11343021/pdf/sciadv.ado2048.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11343021","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11343021?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["CAR-T cell therapy research","Virus-based gene therapy research","Immune Cell Function and Interaction","Herpesvirus 4, Human","Animals","Humans","Epstein-Barr Virus Infections","Mice","Memory T Cells","CD4-Positive T-Lymphocytes","Immunotherapy, Adoptive","Xenograft Model Antitumor Assays","Stem Cells","Immunologic Memory","Lymphoma","Disease Models, Animal"],"mesh_terms":["Memory T Cells","Animals","Disease Models, Animal","Herpesvirus 4, Human","Humans","Immunologic Memory","Lymphoma","Stem Cells","CD4-Positive T-Lymphocytes","Immunotherapy, Adoptive","Epstein-Barr Virus Infections","Xenograft Model Antitumor Assays","Mice"],"keywords":["Adoptive cell transfer","Immunology","Biology","Antigen","T cell","Stem cell","Lymphoma","Cancer research","In vivo","Immune system","Medicine","Cell biology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-10T04:37:27.127349Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}